PAREXEL Expands Global Clinical Logistics Capabilities To Support More Efficient Trial Execution
Boston, MA /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL ), a leading global biopharmaceutical services provider, today announced the expansion of its global Clinical Logistics Services . A new ancillary warehouse in the greater Boston, Massachusetts area in the United States and a significantly enlarged depot in Santiago, Chile will support the Company's ability to assist clients in more effectively managing their global clinical trial material supply requirements. These facilities expand on PAREXEL's existing clinical logistics infrastructure throughout North America, Latin America, Europe, Africa and the Asia/Pacific region. Through logistics control hubs located in 17 countries around the world PAREXEL manages clinical trial supplies in more than 100 countries.
PAREXEL Clinical Logistics Services enable the efficient and reliable execution of clinical trials through streamlined distribution and centralized management of clinical trial supplies. PAREXEL clinical logistics experts manage import/export requirements, as well as end-to-end coordination of the clinical trial material supply chain from planning, sourcing, manufacturing, storage, and distribution through to site management, return, and destruction.
Through PAREXEL's Quality Assurance management system and oversight of Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) compliance, the Company provides clinical trial sponsors with the highest quality standards to meet evolving regulatory requirements. The PAREXEL Laboratory Operations Management System (LOMAS) tracks every sample against trial protocols and maintains a secure lab database.
"We are taking a strategic approach to the biopharmaceutical industry's steadily growing clinical logistics needs. Through the expertise of our clinical logistics leaders around the world and our advanced global facilities we are focused on streamlining the clinical supply chain, and providing comprehensive services to our clients," said Kurt Norris, Corporate Vice President, Clinical Research Services, PAREXEL.
According to Mr. Norris: "Clinical trials are becoming more complex and sponsors find it challenging to organize consistent delivery of trial-related supplies to multiple locations around the world. Expansion of our clinical logistics capabilities in North America and Latin America, in addition to ongoing investments in this area, reflect our commitment to bring greater efficiencies to global trial execution."
PAREXEL Clinical Logistics Services experts are focused on creating value by establishing an optimized clinical materials supply chain. To learn more, access an interactive poster entitled "The Evolution of Clinical Supply Chain Intelligence" at www.PAREXEL.com/clinicalsupplytour . The poster outlines how supply chain complexities can be transformed into business and study intelligence—enabling better decision making.
The PAREXEL Clinical Logistics Services Group provides high quality, centralized coordination of clinical trial supplies, ancillary supplies, and central lab services. Capabilities include supply planning and management, as well as strategic distribution and warehousing infrastructure to handle and transport clinical trial materials to locations worldwide. PAREXEL facilities feature 24/7/365 monitoring systems and innovative temperature control processes that disseminate confirmations of temperature data in real time. Sophisticated technology systems forecast and track shipments, as well as monitor inventory levels and to analyze safety and efficacy results. For more information, visit: http://www.PAREXEL.com/services-and-capabilities/clinical-research/clinical-logistics-services .
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
SOURCE PAREXEL International Corporation